Financial Architects, Inc Immuno Gen, Inc. Transaction History

Financial Architects, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $1,980 - $3,630	-1,100 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$2.41 - $5.91 $2,651 - $6,501	1,100 New	1,100 $3,000
Q1 2019 May 03, 2019	SELL	$2.41 - $5.91 $2,651 - $6,501	-1,100 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$9.52 - $12.15 $913 - $1,166	-96 Reduced 8.03%	1,100 $11,000
Q3 2017 Nov 01, 2017	BUY	$5.4 - $8.47 $6,458 - $10,130	1,196	1,196 $9,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.